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Abstract
Background and aims: Despite advances in our knowledge of effective services for people who use drugs over
the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims
to discuss the historical development of successful epidemiological indicators and to present a framework for extending
them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at
international, national or subnational levels. The ultimate aim is to improve these services in order to reduce health and
social problems among people who use drugs, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV)
infection, crime and legal problems, overdose (death) and other morbidity and mortality.
Methods and results: The framework was developed collaboratively using consensus methods involving nominal
group meetings, review of existing quality standards, repeated email commenting rounds and qualitative analysis of
opinions/experiences from a broad range of professionals/experts, including members of civil society and organisations
representing people who use drugs. Twelve priority candidate indicators are proposed for opioid agonist therapy (OAT),
needle and syringe programmes (NSP) and generic cross-cutting aspects of harm reduction (and potentially other drug)
services. Under the specific OAT indicators, priority indicators included ‘coverage’ , ‘waiting list time’ , ‘dosage’ and
‘availability in prisons’. For the specific NSP indicators, the priority indicators included ‘coverage’ , ‘number of needles/
syringes distributed/collected’ , ‘provision of other drug use paraphernalia’ and ‘availability in prisons’. Among the
generic or cross-cutting indicators the priority indicators were ‘infectious diseases counselling and care’ , ‘take away
naloxone’ , ‘information on safe use/sex’ and ‘condoms’. We discuss conditions for the successful development of the
suggested indicators and constraints (e.g. funding, ideology). We propose conducting a pilot study to test the feasibility
and applicability of the proposed indicators before their scaling up and routine implementation, to evaluate their
effectiveness in comparing service coverage and quality across countries.
Conclusions: The establishment of an improved set of validated and internationally agreed upon best practice
indicators for monitoring harm reduction service will provide a structural basis for public health and epidemiological
studies and support evidence and human rights-based health policies, services and interventions.
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Background
Important advances in interventions for people who use
drugs (PWUD), in particular those who use opioids and
people who inject drugs (PWID), have occurred over re-
cent decades. Harm reduction services such as needle
and syringe programmes (NSP) and opioid agonist ther-
apy (OAT) [1] have been increasingly established, with
90 countries having NSP to some degree and 80 at least
one OAT programme operational by 2016 [2]. This has
contributed to reductions in viral infections (e.g. human
immunodeficiency virus (HIV), hepatitis C virus (HCV))
and bacterial infections (e.g. tuberculosis (TB), sexually
transmissible infections, skin infections), crime, overdose
and mortality among PWUD. Health cost savings are be-
ing achieved globally, where harm reduction is in place,
especially where these services are combined with anti-
retroviral therapy (ART), allowing millions of people liv-
ing with HIV to stay healthy [3–15]. The provision of
naloxone, a drug to reverse overdose, has expanded from
paramedics to drug workers and to PWUD themselves
and their peers [16–18]. Treatments for infectious
diseases (e.g. HIV, hepatitis B virus (HBV)) and new
direct-acting antiviral (DAA) treatments for HCV, when
available, are having large effects on survival and quality
of life and have opened new avenues for effective pre-
vention [19–22]. Evidence on intervention best practice
is mounting and is increasingly based on larger and bet-
ter designed studies [23, 24].
Drug policies have also started to shift, even if the transla-
tion of evidence into policy remains difficult [25–28]. In
some countries, there is cooperation between judicial and
health authorities to mitigate harms associated with the
criminalisation of drug use [29] and explicit or de facto
decriminalisation of drug use [30–32]—these may often go
together [33]—or even legalisation, in the case of cannabis
[34–37]. Human rights-based approaches to drug treatment,
incorporating harm reduction and social integration, have
been implemented in a number of countries despite univer-
sal, national and global drug prohibition policies [38–40].
Despite such positive progress, however, many countries still
have very low implementation levels of evidence-based
programmes, exposing PWUD and the wider society to un-
necessary health risks [13, 15, 41]. Above all, interventions
appear to be frequently lacking for some of the most socially
deprived groups, such as homeless, migrants, sex workers
and prisoners [42–52]. Harm reduction and drug policy
more widely have not been high on the international polit-
ical agenda, with the United Nations General Assembly
Special Session on the World Drug Problem in 2016 being
the first high-level meeting after many years with the aim to
debate drug policy. Also, the global target to reduce new
HIV infections by 50% by 2015 was missed, and the lat-
est UNAIDS (The Joint United Nations Programme on
HIV/AIDS) report suggests that HIV infections among
this group actually increased by one third between 2011
and 2015 [53].
Critically, there are still continuous gaps in informa-
tion on how effectively interventions are actually being
provided; their coverage, quality, client characteristics
and the degree to which they fulfil the needs of different
populations of drug users [13, 15, 54–56]. While in
many countries there are regular—often costly—epide-
miological studies on the characteristics and behaviours
of drug users, the collection of comparable and reliable
monitoring data on the extent and quality of routine in-
terventions (for example NSP) and service implementa-
tion remains rare. Epidemiological studies and routine
analysis of health indicator data are key to evaluating
drug service effectiveness, but they are infrequently ex-
tended to and combined with detailed information on
intervention characteristics [15, 41, 57–59]. A tight
nexus between indicators of quality and drug service
provision and health outcomes has been documented
[60–62]. Despite the wide range of quality standards and
best practice guidelines for drug services on the national
and international level [6, 23, 24, 56], research has
shown that adherence to these guidelines should not be
taken for granted, and there is a need for data that
reflect the reality of actual practice ‘on the ground’
[63, 64]. There is increasing interest in the quality
and coverage of harm reduction services for people
who use drugs and in the development of methodolo-
gies for measuring these [6, 56, 65]. An understanding of
what services are being provided, in what form and the
extent to which they are provided to individual users,
including their views on the provision (where possible
extending to enumeration of costs and if possible—in
separate studies by specialist researchers—modelling
of cost-effectiveness) is critical to the analysis of
public health needs and whether these are adequately
addressed.
This paper aims to identify which standardised data
are needed—and why—for monitoring both the coverage
and quality of harm reduction services [56]. This is not
the type of research question that can be readily addressed
through standard epidemiological methods. Rather, useful
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approaches may include analysis of historical develop-
ments in the area, critical discussion of current best prac-
tices (i.e. indicators in use that have proved successful)
and data gap analysis.
Methods
As a first step, we describe the historical development of
established international monitoring systems and indica-
tors in the field of drugs and health. We then propose a
framework for further indicator development and evalu-
ation in the area of harm reduction (and potentially
other drug services, for examples see the footnotes
below Table 3). This framework was developed using
consensus methods, including nominal group meetings
and email discussions [66, 67] reviewing existing quality
standards [6, 56, 68], to capture and analyse the opinion
and experience from a broad range of professionals/ex-
perts. The participating experts provided different perspec-
tives and expertise (international and national monitoring
system specialists, researchers, harm reduction profes-
sionals, government representatives) and included mem-
bers of civil society organisations representing PWUD and
people living with HIV/HCV. The framework lists candi-
date indicators for OAT, NSP and generic cross-cutting in-
dicators for harm reduction (and potentially other drug)
services. The framework with candidate indicators was de-
veloped in an iterative process of multiple commenting
rounds until a stable consensus list of potential indicators
(and areas for future indicator development) emerged. We
discuss constraints (e.g. funding, ideology) and conditions
for potential successful development of the suggested
candidate indicators.
Results
Historical development of existing drug use monitoring
systems
The global development of indicators in the drugs field
was spearheaded in the area of HIV/AIDS. In 1989, one
of the first common sets of indicators (behavioural) for
people who inject drugs (PWID) was applied across
countries by the World Health Organization (WHO) ‘13
cities study of drug injecting and HIV infection’ [69]. In
1998, the National Institute on Drug Abuse (NIDA),
WHO and UNAIDS formed the ‘Global Research Net-
work on HIV Prevention in Drug-Using Populations’
(GRN) to help control the HIV epidemic among PWID
[70] by discussing best practice and exchanging national
study methods and results in international meetings. The
GRN was succeeded in 2004 by the ‘Reference Group to
the United Nations on HIV and Injecting Drug Use’, a net-
work funded by UNODC, WHO and UNAIDS, to esti-
mate the global spread of HIV among PWID [71–73] and
intervention coverage [13] using common methodology,
which culminated in UN guidance for countries to set
targets for intervention coverage [6, 74] and implementa-
tion [75]. Ongoing global monitoring has more recently
been taken up by UN reporting systems [76, 77] and non-
governmental and academic organisations [2, 78].
In Europe, comparable work on drug use started in 1982
with the ‘Multi-city study of drug misuse in Europe’ [79].
This expert network developed epidemiological indicators
to interpret trends in drug use and their consequences
from routine sources and studies across countries, leading
to the first pan-European drug treatment data monitoring
protocol [80, 81]. European multi-country impact studies
on HIV/AIDS and PWID followed in 1989–1993 [82–87],
leading to an increased interest in preventing HIV trans-
mission in prisons [88–90]. The growing global attention
paid to HIV/AIDS accelerated the urgency to improve re-
sponses for PWID, leading to the creation of a single
agency for the European Union (EU) in the area of drugs.
Since 1995, the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) and its national partners
(the ‘Reitox Network’ (Réseau Européen d Information sur
les Drogues et les Toxicomanies) of National Focal Points,
as well as multiple topic-specific expert networks, have
collaborated to gather evidence on the situation of drugs
and their consequences to support national policymaking
[41, 91–97]. A central area of this work concerns the de-
velopment of the five ‘key epidemiological indicators’ of
drug use and its consequences (general population sur-
veys, population size estimates of PWUD at high risk of
(or already experiencing) negative consequences and that
include hidden populations, infectious diseases—HIV and
viral hepatitis, overdose deaths, treatment demand)
(Table 1) [98–100]. Despite the difficulties of collecting re-
liable data at a pan-European level, [101–103] these are
being relatively well reported (almost all countries
reporting on most indicators, Table 1), and they have
been followed at the global level [73, 104–106].
A smaller number of intervention indicators were also
developed, in the areas of drug treatment and harm re-
duction (Table 2). These concern both the provision of
services (counts of clients entering treatment or syringes
and clients/contacts in NSP) as well as coverage indica-
tors (provision divided by estimates of the population in
need of the service) [15, 107–109]. In 2013, a majority of
countries were able to provide most of the provision in-
dicators. However, reporting of the coverage indicators
was significantly weaker, mainly because they necessitate
additional information, in the form of population size es-
timates for PWUD as their denominators (from Table 1)
(Table 2). Although provision indicators are important,
for example to follow trends over time, they have in-
herent limitations, and additional coverage indicators
are essential.
Rates of drug use or drug injection differ strongly
between countries, and thus, the comparability and
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Table 2 Health and social intervention indicators for people who use opioids and people who inject drugs being used at
European Union level
Intervention Indicators Countries, out of 30,
reporting in 2011–2015a
Data type Additional information
Provision
Drug treatment (total) All clients 30 Counts –
OAT All clients, by OAT medication 30, 30 Counts Legal framework/providers
NSP Syringes provided, clients, contacts, fixed sites,
outreach sites
25, 19, 20, 28, 26 Counts Estimated reporting coverage
(%), NUTS2/3 levelb
Coverage
OAT OAT clients divided by the estimated number
of opioid users (Fig. 1)
20 % Confidence intervals, estimation
methods
NSP Syringes provided divided by the estimated
number of PWID (Fig. 2)
14 % Confidence intervals, estimation
methods
Available at http://www.emcdda.europa.eu/data/stats2016
aYear of reporting data to EMCDDA–the actual study year (year of primary data collection) is mostly 1 year earlier
bNomenclature of Territorial Units for Statistics
Table 1 Epidemiological indicators for people who use drugs being used at European Union level
Domain Indicators Countries, out of 30,
reporting in 2011–
2015b
Data
type
Additional information
Prevalence of drug
use in the general
populationa
Prevalence of lifetime use, last
year use, last month use
25 % Representative (household) surveys with breakdowns by
drug, age, gender, complemented by school surveys in
15-16 year old students (ESPAD) http://www.espad.org/
High-risk drug use/
problem drug usea,c
Population size estimates of
high-risk PWUD including
hidden populations (all,
opioids, stimulants, PWID)
25 Rate/
1000
Confidence intervals, estimation methods
Treatment demanda Clients entering treatment 30 Counts Breakdowns by ever previously treated,
treatment type, prison, main drug, sex,
age at treatment, age at first use, referral
source, living status, education, labour status,
route of administration, frequency of use
Overdose deathsa Number of deaths, average age 30 Counts Breakdowns by gender, toxicology, ICD code
Infectious diseasesa Notifications and prevalence of
HIV/AIDS, HBV, HCV among PWID
Prevalence: HIV 29
HCV 25, HBV 18–16;
notifications: HIV/AIDS
30/29
Counts,
%
Prevalence among young and new PWID
Seizures of drugs Number, quantity in kg 28, 30 Counts,
weights
Seizures by drug class, cannabis plants, tablets/doses
Price, purity/
potency
Price, potency/purity 29, 29 Euro/g,
%
(%THC)e
Sample size, summary statistics, composition (%
MDMAd/(meth)amphetamines)
Drug use in prison Prevalence of lifetime use,
last year use, last month use
10 % Breakdowns by: before/in prison, drug class
Drug law offences Number of: offences, offenders,
either
25, 21, 30 Counts Breakdowns by type (use, supply), drug class
aFive ‘key epidemiological indicators’. Available at http://www.emcdda.europa.eu/data/stats2016
bYear of reporting data to EMCDDA–the actual study year (year of primary data collection) is mostly 1 year earlier
cThis key indicator has been renamed from ‘Problem Drug Use’ (definition: ‘injecting drug use or long duration/regular use of opiates, cocaine and/or
amphetamines’) to ‘High Risk Drug Use’ (definition: ‘recurrent drug use that is causing actual harms (negative consequences) to the person (including dependence
but also other health, psychological or social problems), or is placing the person at a high probability/risk of suffering such harms’). It attempts to define and
estimate the population size of those PWUD that are likely to be in need of services due to having (a high risk of) negative consequences from their drug use,
such as PWID or people who use opioids
d3,4-Methylenedioxymethamphetamine (‘ecstasy’)
eTetrahydrocannabinol
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interpretability of the simpler provision indicators (as
counts, or rates per general population) may be seriously
compromised with regard to the target populations of
people who use opioids or PWID. Nevertheless, coverage
indicators clearly also have limitations, for example uncer-
tainty intervals around central estimates are often large
and estimation methods not uniform, in addition to the
lower reporting rates [41].
However, despite the significant drawbacks, they pro-
vide relatively comparable evidence (‘best available esti-
mates’) across countries with regard to whether services
meet the needs of the target population, with recent data
suggesting that important differences in coverage may
exist between countries in Europe (Figs. 1 and 2). These
coverage indicators have been adopted at global level to
assess policy implementation in the drug field [6, 13, 41,
74]. At the same time, it is clear that they are limited in
terms of giving insight into modalities of provision and
the perspectives of people using the service; thus, de-
veloping additional indicators of service quality is
likely to improve the usefulness and interpretability of
the intervention coverage indicators. Existing quality
standards [6, 56, 68] provide an important basis for
developing epidemiological indicators of service
quality.
Results of the expert group consultation
During 2014 and 2015, an international expert network
began discussions to advance the monitoring and evalu-
ation of best practice in drug-related interventions in
Europe. It recommended focusing on the monitoring of
coverage and quality of harm reduction services, as a
first step to improving best practice implementation of
wider drug services. This could best be achieved by inte-
grating a limited set of additional indicators into the
existing intervention indicators as currently coordinated
by the EMCDDA as well as strengthening the reporting
of existing indicators. Any additional indicators would
then benefit from the ongoing efforts by European coun-
tries to ensure the timeliness, quality and completeness
of data. Candidate indicators should compare key as-
pects of intervention delivery across countries, should be
relatively easy to collect, where possible be evidence-based
and, if not, based on expert consensus, and represent
quality and coverage of services [110]. It was decided
to start in a pragmatic way by producing a ‘frame-
work’ , i.e. mapping a list of potentially suitable candi-
date indicators and areas for future indicators,
building on existing quality standards [6, 56, 68], the
available expert opinions and experience and using
consensus methods, as described above. The candidate
indicators were chosen on their potential to reflect the
structural and procedural quality of harm reduction
services and service coverage [6, 56]. In future work,
similar indicators could be set up for other interven-
tions for PWUD, e.g. antiviral therapy or infectious
disease testing [5, 6, 111]. For the suggested frame-
work with candidate indicators of harm reduction
service quality and coverage (OAT, NSP and ‘generic
cross-cutting’ indicators), see Table 3.
Fig. 1 Estimated percentage of people who use opioids receiving opioid agonist therapy during 1 year (EMCDDA 2016) [41]. Note: data displayed
as uncertainty intervals and point estimates. Estimates are based on latest data available on clients in opioid use treatment (2012–2014) combined
with most recent estimates of opioid use prevalence (2007–2014). Below red dotted line, low (<30%); between red and green dotted lines,
medium (30–50%); above green dotted line, high (>50%)
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Framework of potential indicators and areas for
consideration
As expected, two main interventions were indicated by
the experts as central to harm reduction (mainly, pre-
vention of infectious diseases such as HIV and viral
hepatitis and of opiate-related overdose), namely, NSP
and OAT. Other areas in harm reduction for further
consideration of indicator development, but for practical
reasons not included among the recommended indica-
tors, included ART (both for HIV and viral hepatitis),
consumption rooms and heroin-assisted treatment
(Table 3). Under the specific OAT indicators, priority in-
dicators included ‘coverage’, ‘waiting list time’, ‘dosage’
and ‘availability in prisons’. For the specific NSP indica-
tors, the priority indicators included ‘coverage’, ‘number
of needles/syringes distributed/collected’, ‘provision of
other drug use paraphernalia’ and ‘availability in prisons’.
Among the generic or cross-cutting indicators proposed
for harm reduction services (and potentially other drug
services), the priority indicators were ‘infectious diseases
counselling and care’, ‘take home naloxone’, ‘information
on safe use/sex’ and ‘condoms’ (for details, see Table 3).
Discussion
This consensus study provides a basis for the develop-
ment and implementation of indicators of harm reduc-
tion quality and coverage and highlights further areas of
potential monitoring of best practice intervention.
Twelve priority candidate indicators were identified, on
OAT, NSP and generic service quality aspects. Most of
these seem relatively easy to monitor, consisting of sim-
ple ‘yes/no’ responses or a basic statistic. We propose
conducting a pilot study to test the feasibility and applic-
ability of the proposed indicators before their scaling up,
to evaluate their effectiveness in comparing service qual-
ity across countries. From the experience in Europe, we
suggest that this development should be collaborative
(‘bottom-up’) making use of national and local experience
and involving a broad range of experts and stakeholders
(e.g. professionals, policymakers, representatives of people
who use drugs and/or drug services, harm reduction orga-
nisations) across countries [56].
Important services were not included for monitoring,
e.g. ART, mainly due to difficulties in finding a simple
operationalisation or a key statistic from routine data
that is readily available for all countries to be reported
(such data may be obtained by special surveys; however,
these are costly). While NSP and OAT are services that
are specific for people who use opioids or PWID, re-
spectively, and thus client numbers can be interpreted
more easily, for ART this is not the case and in practice
it is harder to come by reliable numbers for specific at-
risk groups in treatment, e.g. PWID or men who have
sex with men. Other services that are important but
were not included are heroin-assisted treatment, drug
consumption rooms/safer injection facilities, drug testing
and water provision at rave parties, police interactions
with drug users and interventions in special settings
such as prisons. Again, their non-inclusion resulted not
because they were considered unimportant but rather
Fig. 2 Estimated number of syringes provided annually through specialised programmes per person who injects drugs (EMCDDA 2016) [41]. Note:
data displayed as uncertainty intervals and point estimates. Estimates are based on latest data available on syringe provision (2013–2014) combined
with most recent estimates of PWID prevalence (2008–2014). Below red dotted line, low (<100); between red and green dotted lines, medium (100–200);
above green dotted line, high (>200).
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they were thought to be harder to monitor (e.g. police
interactions) or to be partly overlapping with other indi-
cators (e.g. safer injection rooms with NSP). However,
indicators not included here might still be considered
for implementation by individual countries depending
on national context and priorities. For example, in many
Latin American and Caribbean countries, stimulant use
is more important than opioids, which might require
adapting the indicators [2, 112]. Our approach might be
extended to areas surrounding the actual implementa-
tion of drug services. For example, drug policy indicators
could be considered for monitoring, e.g. sentencing
practices and minimum quantities of drugs allowed for
personal use, decriminalisation/liberalisation of drug
laws or drug treatment regulations may have profound
impact on health and well-being of PWUD. A recent
study proposed a framework to classify countries by
Table 3 Framework for the development of indicators for
quality monitoring of harm reduction services, with a focus on
opioid agonist therapy (OAT) and needle and syringe
programmes (NSP); priority indicators are in italics
Specific OAT indicators may includea:
Coverage of estimated opioid user population (%, see Fig. 1)
Waiting time to first treatment admission (months)
Methadone/buprenorphine dosage (grams)
OAT available (including new initiation) in prisons (in all /in some /no)
OAT medicine covered by state /health insurance (yes /partly /no)
Illicit drug consumption tolerated (after dose induction phase) (yes /no)
Diagnosis or detailed assessment of current substance use,
individualised treatment planning (yes /no)
Take home OAT available (yes /no)
Counselling required (yes /no)
Specific NSP indicators may includea:
Coverage of estimated PWID population (syringes /PWID /year, see Fig. 2)
Annual number of needles /syringes distributed and collected
(administrative data, and /or estimated by weight)b
Provision of drug use equipment and injecting paraphernalia (including
for non-injected use e.g. foils for heroin chasing, stems and filters for
crack smoking) (in all /in some /no)
NSP available in prisons (in all /in some /no)
Coverage of all undertaken injections (syringes /100 injections)
Restrictions in numbers of syringes distributed per contact (yes /no)
Type of syringes (% low dead space, acceptance by users)
Modality (specialised NSP, outreach, pharmacy, other, e.g. drug
treatment service)
Brief opportunistic motivational interventions provided (yes /no)
Generic cross-cutting indicators for harm reduction (and other drug
services) may includea:
Infectious diseases counselling, testing, vaccination and referrals (e.g.
HIV, HCV, HBV, TB) (in all /in some /no)
Take away naloxone provided (in all /in some /no)
Information provided on safer use, injecting and safer sex (in all /in some /no)
Condoms provided (in all /in some /no)
Accessibility: opening times and geographic coverage, outreach
activities, costs to clients, no age limits, no parental consent
requirements, targeted programmes for special populations (e.g.
(pregnant) women, sex workers, underage users) (to construct overall
index score: high /medium /low)
Integration /cooperation with other services and continuity of care:
e.g. shared location /referrals to NSP, OAT, infectious diseases
counselling and testing, antiviral and other medical treatment and
care, overdose prevention, social support, housing, education,
employment services (in all /in some /no)
Regular consultation with law enforcement /community /neighbourhood:
avoiding nuisance and conflict, improving safety for both clients and
community (index: high /medium /low)
Regular consultation with the users of the service: feedback,
evaluation, client satisfaction (index: high /medium /low)
Table 3 (Continued)
Assessment procedures: risk behaviours, needs, health status,
informed consent, data confidentiality, written client records
(index: high /medium /low)
Psycho-social interventions provided (with or without medication):
(yes /no)
Frequency of contact with a counsellor /social worker (times per month)
Staff qualification, multidisciplinarity, education and (ongoing) training
(index: high /medium /low)
Case /contact management follows protocol /guidelines (yes /no,
specify which)
Type of funding source: private /public; national /international, etc.;
and security of funding (per client, grant-based, etc.), utilisation
monitoring (treatment slots used), peer support /aid (to construct
an overall index score on funding continuity and reliability: high
/medium /low)
aThe quality indicators listed are mostly structural and procedural [56].
Outcome indicators are limited to OAT and NSP coverage estimates. Other
outcome indicators may be considered (e.g. client retention and return rates,
reductions in drug use, crime, improvements in health, etc.), but given their
complexity, this may be more appropriate to assess in detailed service
evaluation studies at national or local level [171] (although note [110]). Further
work may be needed to link up more strongly with recently adopted EU
quality standards [68]. Other harm reduction and drug interventions to be
considered for monitoring may include antiviral and antibacterial therapy (e.g.
HIV, HCV, HBV, TB), heroin-assisted treatment, drug consumption rooms/safer
injecting facilities, testing drug content and handing out water at rave parties
and similar events, police interactions with drug users affecting service
utilisation, interventions in special settings (e.g. prisons, mobile or outreach
interventions), social interventions, e.g. relating to children or family of PWUD,
and monitoring and may even extend to drug policy indicators (e.g. minimum
quantities of drugs allowed for personal use, sentencing practise, medical use
of cannabis, decriminalisation/liberalisation of drug laws, drug treatment
regulations, e.g. allowing opioid agonist therapy through primary caregivers),
continuity of care following prison release or treatment discharge
bMeasuring infection rates in returned syringes may form an important and
cost-effective method for monitoring prevalence and incidence of infection in
the population [135, 136].
Measures of central tendency (e.g. mean, median) may be complemented by
measures of variability (e.g. range, interquartile range) to better capture
intra- and inter-national variation.
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their models of ‘governance of addictions’ from an analysis
of national drug strategies [33]. Monitoring both drug pol-
icies and their actual implementation and practice might
reveal important discrepancies between the two, providing
key policy relevant information [113, 114].
Indicators for the quality of drug services must be
closely linked to epidemiological data and methods. The
development of OAT and NSP coverage indicators
(Figs. 1 and 2) was made possible by the increased avail-
ability of routine epidemiological monitoring data and
the increased use of statistical modelling methods. The
methods to estimate population sizes of PWUD/PWID
originated in biology and continue to be improved for
epidemiological application even if they have not essen-
tially changed [97, 102, 105, 115–129]. Mathematical
and statistical modelling has more generally been useful
to improve our understanding of intervention effective-
ness and cost-effectiveness as well as to give insight in
potential epidemic courses and processes, thus providing
some basis to evaluate interventions [95–97, 130–134].
Different types of intervention have been studied using
mathematical models, such as impact of needle exchange
programmes [135, 136], impact of behavioural changes
[137] and impact of treatment on transmission [138, 139].
Recent studies suggest that molecular analyses of infec-
tious diseases may also provide added value to epidemio-
logical surveillance as a basis for evaluating interventions
[48, 140–143]. Moreover, comprehensive reviews of
epidemiological data (and intervention effectiveness
and implementation) have been carried out to estimate
the burden of disease and quality of life, providing a
means to compare health and societal impact of inter-
ventions across different diseases including through
cost-effectiveness analyses [144–148]. Indicators should
not be limited to national-level data only. Having subna-
tional breakdowns—by city or region—would be critical to
understand within-country variation in epidemiological
trends and intervention impact [149–152].
Apart from using the proposed indicators individually,
they might be used for system-level evaluation to moni-
tor and guide service integration and referral at national
level. For example, it is important to use these indicators
together to assess the comprehensiveness of harm re-
duction programming, given the evidence that harm re-
duction interventions are most effective when used in
combination [138, 153]. Another example of a combined
approach may be provided by a ‘harm reduction cascade’
model, similar to the recently proposed HIV or HCV
care cascades [19, 154, 155], where the ‘flow’ of people
who use drugs would be modelled through a tailored set
of services, ranging from catering the needs of incidental
or recreational users to those who inject drugs or are
heavily dependent, and/or may have a range of health
and social problems. The HIV and HCV cascade model
enables the identification of gaps in health system per-
formance by estimating the percentage of infected who
know their status, percentage of those in care, percent-
age of those on ART and percentage of those with
undetectable viral load/sustained virologic response.
Care cascade indicators relate to the timely provision of
ART for HIV and best medical practices for HBV, HCV
and other diseases (endocarditis, methicillin-resistant
staphylococcus aureus (MRSA), anthrax, TB, etc.) and
might similarly be developed for drug prevention, treat-
ment and harm reduction measures. Another example
focuses on the interface between judicial and public
health interventions. This includes the analysis of police
interactions with drug users in the context of their ser-
vice utilisation, policy indicators (e.g. minimum quan-
tities of drugs allowed for personal use, sentencing
practice, medical use of cannabis, decriminalisation/lib-
eralisation of drug laws [37]) and the continuity of care
following prison release [156, 157].
The feasibility of monitoring drug service implementa-
tion will depend on resources in countries and may
therefore be more limited in low and middle income
countries. However, where a country lacks the resources
to implement and further develop these indicators, the
proposed framework may be useful to document the ab-
sence of data in specific areas, even if in a rudimentary
form (e.g. a binary ‘yes/no’ checklist). Monitoring per-
formance should be evaluated only after several years of
data collection using performance indicators such as the
number of countries providing data and assessments of
the credibility of the methods and sources behind the
available data. In practice it may take many years to arrive
at a high reporting rate with good quality data, and main-
taining a long-term perspective is necessary. With respect
to clinical services performance, which is evaluated by
health insurance systems and/or national health authorities
[158], monitoring drug services may pose specific difficul-
ties due to their multi-disciplinary nature and as they may
depend on different government and private entities and
multiple funding sources. Service provision may thus de-
pend on the type of service providers (public, private, non-
governmental organizations including peer-driven initia-
tives, general medical practitioners), funding sources (cen-
tral government, local and regional governments, social
health insurance, private and other sources) and funding
mechanisms (grants, treatment case, daily costs, fee for ser-
vice or payment by result) [159]. Other aspects of funding
might also impact on service performance, quality and out-
comes—such as the way providers are chosen and the ways
services are paid for, e.g. block grant, capitation, payment
for activity or payment for outcome [160], although the
evidence of how the funding provisions influence outcomes
is mixed [161–163]. Additionally, disaggregated spending
records could indicate whether programmes invest in
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adequate numbers of well-trained staff and procure quality
commodities that meet the needs of the people accessing
the service—all related to the quality of service provision.
While we recommend monitoring harm reduction funding,
this did not make it into the 12 priority indicators, as our
focus has been on the service coverage and quality per se.
While investment in itself would not denote quality,
whether a programme is funded by government or an
international donor can have implications for its sustain-
ability that are important to monitor. There are several
countries in Europe, as well as globally, facing issues with
harm reduction sustainability and funding. It would be
timely to consider a separate pilot study on the use of indi-
cators relating to harm reduction spending.
There are several limitations to this analysis. While we
were able to identify a set of priority candidate indica-
tors using a consensus approach, we cannot at this stage
present empirical evidence on the potential problems or
advantages associated with implementation of these indi-
cators. However, with the established, mostly epidemio-
logical, indicators (Tables 1 and 2), this was a process of
trial and error where a number of countries start jointly
piloting such data collection using an agreed protocol,
exchange experiences in regular working group meetings
and improve quality and comparability of data collection
practice, adjusting the protocol if necessary. A prior step
could be to carry out specific literature reviews on each
of the indicators; however, this was beyond the scope of
our study. Also, we were unable to grade the informa-
tion and suggestions obtained from our expert group by
levels of evidence quality [164], again this was beyond
the scope of our study, and given the broad area we
cover would have not been feasible. If in a future step
specific reviews are carried out on each indicator it
would be important to attempt grading the evidence for
each of them, although such evidence is likely to be
scarce and in need of being generated. Our consensus
approach was not a formal Delphi study and could as
such be criticised. However, we did include various con-
sensus methods (expert meetings, repeated email com-
menting rounds) [66, 67]. We believe it is unlikely the
results would have differed much depending on the
exact consensus approach, given that all participants
agreed with the final version of framework and indicators.
We have also not been able to identify clear candidate in-
dicators for monitoring patient values and preferences re-
garding harm reduction services, although further work
might well be able to define such indicators, as has been
already attempted in drug treatment research [165–170].
Finally, the services here discussed and for which we
propose to develop indicators are ‘services’ in the form of
programmes that are established by governments or pri-
vate professional organisations and run for the benefit of
‘society’ or, at least putatively, in the benefit of clients or
patients. In organisational terms, these are top-down ser-
vices. What is not discussed in this article is the array of
self-financed or funded users’ groups and their activities
both in helping each other and also in providing useful
and needed critique of the top-down services and policies.
There is clearly a need for further work on this area with
strong involvement of the target populations and their or-
ganisational representatives that services are serving.
Conclusions
We propose a framework for the further development of
indicators of coverage and quality of harm reduction ser-
vices, as a first step to improving best practice implemen-
tation in the drug field. This is based on the successful
development of established monitoring systems and indi-
cators, and an international consensus exercise. This
framework might be especially of use for professionals in
charge of monitoring and/or funding service implementa-
tion and quality at higher (e.g. national, international)
levels of aggregation, in addition to providing some guid-
ance at the local and individual service levels. From the
framework, 12 priority candidate indicators emerge that
are conceptually simple, likely suitable to be collected on a
routine basis, and should provide comparable key evi-
dence on the quality and coverage of opioid agonist ther-
apy, needle and syringe programmes and generic drug
service aspects. We propose conducting a pilot study to
test the feasibility and applicability of the proposed indica-
tors before their scaling up and routine implementation,
to evaluate their effectiveness in comparing service quality
across countries. The implementation of a limited set of
validated and internationally agreed indicators for moni-
toring harm reduction service best practice will provide a
stronger basis for future public health and epidemiological
studies, in order to advance evidence-based health policy.
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